Skip to content

Author

E. Solomou

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.

A 69-year-old female with newly diagnosed MLNFGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma remains in complete remission at 17 months after pemigatinib initiation, with treatment-related toxicity being manageable through dose modifications and temporary interr...

C. Stafylidis, E. Variami, E. Lakiotaki et al. · 0 citations
Open access Aug 2026

Calibrated and explainable multiparametric MRI radiomics for differentiating tumor positive disease from treatment-related changes in glioblastoma

A calibrated and explainable multiparametric MRI radiomics model showed robust internal performance in differentiating tumor from treatment effects in post-treatment GBM.

Rafail C. Christodoulou, Georgios Vamvouras, M. Esmeraldo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.